SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ASND

Ascendis Pharma A/S (NASDAQ:ASND)

DK · Delayed Price · Currency is USD
Healthcare · Biotechnology
$252.73-$3.23 (-1.26%)
 
Market cap
$16.6B
Insider Score
Health Score
Analyst consensus
Listed since
Jan 28, 2015
Market Cap$16.58B+20.1%
Revenue (ttm)$1.21B+86.9%
Net Income$890.37M+482.2%
EPS$13.52+434.7%
Shares Out65.60M
PE Ratio16.21
Forward PE25.75
Dividendn/a
Ex-Dividend Daten/a
Volume602,891
Open$254.72
Previous Close$255.96
Day's Range$251.45 - $256.63
52-Week Range$188.08 - $282.15
Beta0.40
AnalystsBuy
Price Target$310.69(+22.93%)
Earnings DateFeb 10, 2027

About ASND

Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.

Address
Tuborg Boulevard 12, Hellerup, CR, 2900, DK
Market Cap
16.58 billion
Employees
1,189
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$10.79M
Bought
$777.07K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
10 Buy0 Hold0 SellAvg target $302.69 (+19.8%)

10 firms rating ASND in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Strong
From ASND’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-1.26%
5 Days
-8.10%
1 Month
+5.79%
6 Months
+2.11%
1 Year
+20.07%

$ASND stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ASND holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ASND's directors and management

Net Shares Purchased by Insiders−20k−10k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ASND Estimated quarterly lobbying spending

Source: U.S. Senate LDA

ASND Revenue by Segment or Geography

ASND's latest filing doesn't break out revenue by segment.

Source: SEC EDGAR (10-Q/10-K)

U.S. Patents

New ASND patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ASND from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in ASND

TCAFT. Rowe Capital Appreciation Equity ETF$273.35M
IBBiShares Biotechnology ETF$122.90M
IWPiShares Russell Mid-Cap Growth ETF$72.48M
IWRiShares Russell Mid-Cap ETF$58.22M
IWFiShares Russell 1000 Growth ETF$48.67M
SQSSapient Quality Select ETF$35.75M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from ASND’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
98
News & Sentiment
20% of score
72

News check: Strong Q3 earnings with 89% revenue surge, analyst price target raise to $346, outperform rating, though some valuation debate exists.

Recent Insider Activity

Buys
9
Sells
4
Buy Value
$777.07K
Distinct Buyers
2

Insider Score Trend Over Time

-2.0 since Sep 13
0255075100Sep 13 — Insider Score 59.9Sep 14 — Insider Score 57.6Sep 15 — Insider Score 56.4Sep 16 — Insider Score 54.6Sep 17 — Insider Score 53.5Sep 18 — Insider Score 52.9Sep 19 — Insider Score 52.8Sep 20 — Insider Score 52.8Sep 21 — Insider Score 52.4Sep 22 — Insider Score 51.7Sep 23 — Insider Score 50.1Sep 24 — Insider Score 49.5Sep 25 — Insider Score 65.6Sep 26 — Insider Score 65.1Sep 27 — Insider Score 65.3Sep 28 — Insider Score 65.3Sep 29 — Insider Score 66.2Sep 30 — Insider Score 64.6Oct 1 — Insider Score 65.1Oct 2 — Insider Score 54.0Oct 3 — Insider Score 64.8Oct 4 — Insider Score 65.0Oct 5 — Insider Score 63.7Oct 6 — Insider Score 63.0Oct 7 — Insider Score 64.0Oct 8 — Insider Score 63.8Oct 9 — Insider Score 63.5Oct 10 — Insider Score 63.1Oct 11 — Insider Score 64.3Oct 12 — Insider Score 64.5Oct 13 — Insider Score 64.3Oct 14 — Insider Score 64.0Oct 15 — Insider Score 63.9Oct 16 — Insider Score 63.6Oct 17 — Insider Score 63.5Oct 18 — Insider Score 64.0Oct 19 — Insider Score 63.8Oct 20 — Insider Score 63.8Oct 21 — Insider Score 62.2Oct 22 — Insider Score 62.3Oct 23 — Insider Score 62.2Oct 24 — Insider Score 62.2Oct 25 — Insider Score 61.8Oct 26 — Insider Score 61.8Oct 27 — Insider Score 61.9Oct 28 — Insider Score 61.9Oct 29 — Insider Score 62.0Oct 30 — Insider Score 60.8Oct 31 — Insider Score 60.5Nov 1 — Insider Score 60.9Nov 2 — Insider Score 61.0Nov 3 — Insider Score 60.4Nov 4 — Insider Score 60.2Nov 5 — Insider Score 59.6Nov 6 — Insider Score 59.1Nov 7 — Insider Score 58.4Nov 8 — Insider Score 59.4Nov 9 — Insider Score 59.8Nov 10 — Insider Score 58.7Nov 11 — Insider Score 57.9Sep 13Oct 12Nov 11

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

PEPTREX Peptide ETF10.61%
FPXEFirst Trust IPOX Europe Equity Opportunities ETF6.63%
AFOSARS Focused Opportunity Strategy ETF3.79%
AADRAdvisorShares Dorsey Wright3.32%
SQSSapient Quality Select ETF2.83%
TMEDT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF2.34%
TCAFT. Rowe Capital Appreciation Equity ETF2.33%
EXUSNomura Focused International Core ETF2.18%
FDGAmerican Century Focused Dynamic Growth ETF1.87%
AIIQAI Powered International Equity ETF1.77%
FHH.TOFirst Trust AlphaDEX U.S. Health Care Sector Index ETF1.53%
BBPVirtus Biotech ETF1.53%

Weight is the stock’s share of each fund’s holdings.